nimodipine has been researched along with Retinal Artery Occlusion in 3 studies
Nimodipine: A calcium channel blockader with preferential cerebrovascular activity. It has marked cerebrovascular dilating effects and lowers blood pressure.
nimodipine : A dihydropyridine that is 1,4-dihydropyridine which is substituted by methyl groups at positions 2 and 6, a (2-methoxyethoxy)carbonyl group at position 3, a m-nitrophenyl group at position 4, and an isopropoxycarbonyl group at position 5. An L-type calcium channel blocker, it acts particularly on cerebral circulation, and is used both orally and intravenously for the prevention and treatment of subarachnoid hemorrhage from ruptured intracranial aneurysm.
Retinal Artery Occlusion: Sudden ISCHEMIA in the RETINA due to blocked blood flow through the CENTRAL RETINAL ARTERY or its branches leading to sudden complete or partial loss of vision, respectively, in the eye.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kleffner, I | 1 |
| Ringelstein, EB | 1 |
| Stupp, N | 1 |
| Niederstadt, TU | 1 |
| Young, P | 1 |
| Woolridge, D | 1 |
| Stefanelli, M | 1 |
| Hoppe, B | 1 |
| Wildemann, B | 1 |
| Schülin, C | 1 |
| Storch-Hagenlocher, B | 1 |
| Hacke, W | 1 |
| Dithmar, S | 1 |
| Kirchhof, K | 1 |
| Jansen, O | 1 |
| Breitbart, A | 1 |
3 other studies available for nimodipine and Retinal Artery Occlusion
| Article | Year |
|---|---|
Neurological picture. Susac's syndrome: effective combination of immunosuppression and antiplatelet treatment.
Topics: Adolescent; Aspirin; Brain Diseases; Corpus Callosum; Female; Glucocorticoids; Hearing Loss; Humans; | 2006 |
Susac syndrome with frontal intermittent rhythmic delta activity (FIRDA).
Topics: Adult; Brain Diseases; Calcium Channel Blockers; Delta Rhythm; Gait Disorders, Neurologic; Hearing L | 2006 |
Susac's syndrome: improvement with combined antiplatelet and calcium antagonist therapy.
Topics: Adult; Aspirin; Calcium Channel Blockers; Cerebrovascular Disorders; Drug Combinations; Female; Hear | 1996 |